Skip to main content
Top
Published in: BMC Immunology 1/2008

Open Access 01-12-2008 | Research article

Functional imaging of interleukin 1 beta expression in inflammatory process using bioluminescence imaging in transgenic mice

Authors: Limei Li, Zhaoliang Fei, Jianke Ren, Ruilin Sun, Zhihui Liu, Zhejin Sheng, Long Wang, Xia Sun, Jun Yu, Zhugang Wang, Jian Fei

Published in: BMC Immunology | Issue 1/2008

Login to get access

Abstract

Background

Interleukin 1 beta (IL-1β) plays an important role in a number of chronic and acute inflammatory diseases. To understand the role of IL-1β in disease processes and develop an in vivo screening system for anti-inflammatory drugs, a transgenic mouse line was generated which incorporated the transgene firefly luciferase gene driven by a 4.5-kb fragment of the human IL-1β gene promoter. Luciferase gene expression was monitored in live mice under anesthesia using bioluminescence imaging in a number of inflammatory disease models.

Results

In a LPS-induced sepsis model, dramatic increase in luciferase activity was observed in the mice. This transgene induction was time dependent and correlated with an increase of endogenous IL-1β mRNA and pro-IL-1β protein levels in the mice. In a zymosan-induced arthritis model and an oxazolone-induced skin hypersensitivity reaction model, luciferase expression was locally induced in the zymosan injected knee joint and in the ear with oxazolone application, respectively. Dexamethasone suppressed the expression of luciferase gene both in the acute sepsis model and in the acute arthritis model.

Conclusion

Our data suggest that the transgenic mice model could be used to study transcriptional regulation of the IL-1β gene expression in the inflammatory process and evaluation the effect of anti-inflammatory drug in vivo.
Appendix
Available only for authorised users
Literature
1.
go back to reference Dinarello CA: Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol. 1998, 16 (5-6): 457-499. 10.3109/08830189809043005.CrossRefPubMed Dinarello CA: Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol. 1998, 16 (5-6): 457-499. 10.3109/08830189809043005.CrossRefPubMed
2.
go back to reference Dinarello CA: Biologic basis for interleukin-1 in disease. Blood. 1996, 87 (6): 2095-2147.PubMed Dinarello CA: Biologic basis for interleukin-1 in disease. Blood. 1996, 87 (6): 2095-2147.PubMed
3.
go back to reference Sasaki H, Sato T, Yamauchi N, Okamoto T, Kobayashi D, Iyama S, Kato J, Matsunaga T, Takimoto R, Takayama T, Kogawa K, Watanabe N, Niitsu Y: Induction of heat shock protein 47 synthesis by TGF-beta and IL-1 beta via enhancement of the heat shock element binding activity of heat shock transcription factor 1. J Immunol. 2002, 168 (10): 5178-5183.CrossRefPubMed Sasaki H, Sato T, Yamauchi N, Okamoto T, Kobayashi D, Iyama S, Kato J, Matsunaga T, Takimoto R, Takayama T, Kogawa K, Watanabe N, Niitsu Y: Induction of heat shock protein 47 synthesis by TGF-beta and IL-1 beta via enhancement of the heat shock element binding activity of heat shock transcription factor 1. J Immunol. 2002, 168 (10): 5178-5183.CrossRefPubMed
4.
go back to reference Shahbakhti H, Watson RE, Azurdia RM, Ferreira CZ, Garmyn M, Rhodes LE: Influence of eicosapentaenoic acid, an omega-3 fatty acid, on ultraviolet-B generation of prostaglandin-E2 and proinflammatory cytokines interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 in human skin in vivo. Photochem Photobiol. 2004, 80 (2): 231-235. 10.1562/2004-01-27-RA-066.1.CrossRefPubMed Shahbakhti H, Watson RE, Azurdia RM, Ferreira CZ, Garmyn M, Rhodes LE: Influence of eicosapentaenoic acid, an omega-3 fatty acid, on ultraviolet-B generation of prostaglandin-E2 and proinflammatory cytokines interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 in human skin in vivo. Photochem Photobiol. 2004, 80 (2): 231-235. 10.1562/2004-01-27-RA-066.1.CrossRefPubMed
5.
go back to reference Keystone EC, Jaglal S, Shore A: Interleukin 1 and interleukin 2 generation by peripheral blood cells from patients with ankylosing spondylitis. J Rheumatol. 1986, 13 (5): 944-947.PubMed Keystone EC, Jaglal S, Shore A: Interleukin 1 and interleukin 2 generation by peripheral blood cells from patients with ankylosing spondylitis. J Rheumatol. 1986, 13 (5): 944-947.PubMed
6.
go back to reference Lanzrein AS, Johnston CM, Perry VH, Jobst KA, King EM, Smith AD: Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. Alzheimer Dis Assoc Disord. 1998, 12 (3): 215-227. 10.1097/00002093-199809000-00016.CrossRefPubMed Lanzrein AS, Johnston CM, Perry VH, Jobst KA, King EM, Smith AD: Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. Alzheimer Dis Assoc Disord. 1998, 12 (3): 215-227. 10.1097/00002093-199809000-00016.CrossRefPubMed
7.
go back to reference Cannon JG, Friedberg JS, Gelfand JA, Tompkins RG, Burke JF, Dinarello CA: Circulating interleukin-1 beta and tumor necrosis factor-alpha concentrations after burn injury in humans. Crit Care Med. 1992, 20 (10): 1414-1419. 10.1097/00003246-199210000-00009.CrossRefPubMed Cannon JG, Friedberg JS, Gelfand JA, Tompkins RG, Burke JF, Dinarello CA: Circulating interleukin-1 beta and tumor necrosis factor-alpha concentrations after burn injury in humans. Crit Care Med. 1992, 20 (10): 1414-1419. 10.1097/00003246-199210000-00009.CrossRefPubMed
8.
go back to reference Casey LC, Balk RA, Bone RC: Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med. 1993, 119 (8): 771-778.CrossRefPubMed Casey LC, Balk RA, Bone RC: Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med. 1993, 119 (8): 771-778.CrossRefPubMed
9.
go back to reference Fisher CJ, Slotman GJ, Opal SM, Pribble JP, Bone RC, Emmanuel G, Ng D, Bloedow DC, Catalano MA: Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med. 1994, 22 (1): 12-21. 10.1097/00003246-199401000-00267.CrossRefPubMed Fisher CJ, Slotman GJ, Opal SM, Pribble JP, Bone RC, Emmanuel G, Ng D, Bloedow DC, Catalano MA: Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med. 1994, 22 (1): 12-21. 10.1097/00003246-199401000-00267.CrossRefPubMed
10.
go back to reference Fisher CJ, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL, et al.: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. Jama. 1994, 271 (23): 1836-1843. 10.1001/jama.271.23.1836.CrossRefPubMed Fisher CJ, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL, et al.: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. Jama. 1994, 271 (23): 1836-1843. 10.1001/jama.271.23.1836.CrossRefPubMed
11.
go back to reference Antin JH, Weinstein HJ, Guinan EC, McCarthy P, Bierer BE, Gilliland DG, Parsons SK, Ballen KK, Rimm IJ, Falzarano G, et al.: Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood. 1994, 84 (4): 1342-1348.PubMed Antin JH, Weinstein HJ, Guinan EC, McCarthy P, Bierer BE, Gilliland DG, Parsons SK, Ballen KK, Rimm IJ, Falzarano G, et al.: Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood. 1994, 84 (4): 1342-1348.PubMed
12.
go back to reference Cogswell JP, Godlevski MM, Wisely GB, Clay WC, Leesnitzer LM, Ways JP, Gray JG: NF-kappa B regulates IL-1 beta transcription through a consensus NF-kappa B binding site and a nonconsensus CRE-like site. J Immunol. 1994, 153 (2): 712-723.PubMed Cogswell JP, Godlevski MM, Wisely GB, Clay WC, Leesnitzer LM, Ways JP, Gray JG: NF-kappa B regulates IL-1 beta transcription through a consensus NF-kappa B binding site and a nonconsensus CRE-like site. J Immunol. 1994, 153 (2): 712-723.PubMed
13.
go back to reference Sadikot RT, Jansen ED, Blackwell TR, Zoia O, Yull F, Christman JW, Blackwell TS: High-dose dexamethasone accentuates nuclear factor-kappa b activation in endotoxin-treated mice. Am J Respir Crit Care Med. 2001, 164 (5): 873-878.CrossRefPubMed Sadikot RT, Jansen ED, Blackwell TR, Zoia O, Yull F, Christman JW, Blackwell TS: High-dose dexamethasone accentuates nuclear factor-kappa b activation in endotoxin-treated mice. Am J Respir Crit Care Med. 2001, 164 (5): 873-878.CrossRefPubMed
14.
go back to reference Contag PR, Olomu IN, Stevenson DK, Contag CH: Bioluminescent indicators in living mammals. Nat Med. 1998, 4 (2): 245-247. 10.1038/nm0298-245.CrossRefPubMed Contag PR, Olomu IN, Stevenson DK, Contag CH: Bioluminescent indicators in living mammals. Nat Med. 1998, 4 (2): 245-247. 10.1038/nm0298-245.CrossRefPubMed
15.
go back to reference Carlsen H, Moskaug JO, Fromm SH, Blomhoff R: In vivo imaging of NF-kappa B activity. J Immunol. 2002, 168 (3): 1441-1446.CrossRefPubMed Carlsen H, Moskaug JO, Fromm SH, Blomhoff R: In vivo imaging of NF-kappa B activity. J Immunol. 2002, 168 (3): 1441-1446.CrossRefPubMed
16.
go back to reference Jeon YJ, Han SH, Lee YW, Lee M, Yang KH, Kim HM: Dexamethasone inhibits IL-1 beta gene expression in LPS-stimulated RAW 264.7 cells by blocking NF-kappa B/Rel and AP-1 activation. Immunopharmacology. 2000, 48 (2): 173-183. 10.1016/S0162-3109(00)00199-5.CrossRefPubMed Jeon YJ, Han SH, Lee YW, Lee M, Yang KH, Kim HM: Dexamethasone inhibits IL-1 beta gene expression in LPS-stimulated RAW 264.7 cells by blocking NF-kappa B/Rel and AP-1 activation. Immunopharmacology. 2000, 48 (2): 173-183. 10.1016/S0162-3109(00)00199-5.CrossRefPubMed
17.
go back to reference Tsao PW, Suzuki T, Totsuka R, Murata T, Takagi T, Ohmachi Y, Fujimura H, Takata I: The effect of dexamethasone on the expression of activated NF-kappa B in adjuvant arthritis. Clin Immunol Immunopathol. 1997, 83 (2): 173-178. 10.1006/clin.1997.4333.CrossRefPubMed Tsao PW, Suzuki T, Totsuka R, Murata T, Takagi T, Ohmachi Y, Fujimura H, Takata I: The effect of dexamethasone on the expression of activated NF-kappa B in adjuvant arthritis. Clin Immunol Immunopathol. 1997, 83 (2): 173-178. 10.1006/clin.1997.4333.CrossRefPubMed
18.
go back to reference Zhang Y, Xu J, Zhong N: [Proinflammatory cytokine stimulated NF-kappa B activation and the effect of dexamethasone in the human airway epithelial cells]. Zhonghua Jie He He Hu Xi Za Zhi. 2000, 23 (5): 296-299.PubMed Zhang Y, Xu J, Zhong N: [Proinflammatory cytokine stimulated NF-kappa B activation and the effect of dexamethasone in the human airway epithelial cells]. Zhonghua Jie He He Hu Xi Za Zhi. 2000, 23 (5): 296-299.PubMed
19.
go back to reference Greten FR, Arkan MC, Bollrath J, Hsu LC, Goode J, Miething C, Goktuna SI, Neuenhahn M, Fierer J, Paxian S, Van Rooijen N, Xu Y, O'Cain T, Jaffee BB, Busch DH, Duyster J, Schmid RM, Eckmann L, Karin M: NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell. 2007, 130 (5): 918-931. 10.1016/j.cell.2007.07.009.PubMedCentralCrossRefPubMed Greten FR, Arkan MC, Bollrath J, Hsu LC, Goode J, Miething C, Goktuna SI, Neuenhahn M, Fierer J, Paxian S, Van Rooijen N, Xu Y, O'Cain T, Jaffee BB, Busch DH, Duyster J, Schmid RM, Eckmann L, Karin M: NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell. 2007, 130 (5): 918-931. 10.1016/j.cell.2007.07.009.PubMedCentralCrossRefPubMed
20.
go back to reference Deinzer R, Granrath N, Stuhl H, Twork L, Idel H, Waschul B, Herforth A: Acute stress effects on local Il-1beta responses to pathogens in a human in vivo model. Brain Behav Immun. 2004, 18 (5): 458-467. 10.1016/j.bbi.2003.11.008.CrossRefPubMed Deinzer R, Granrath N, Stuhl H, Twork L, Idel H, Waschul B, Herforth A: Acute stress effects on local Il-1beta responses to pathogens in a human in vivo model. Brain Behav Immun. 2004, 18 (5): 458-467. 10.1016/j.bbi.2003.11.008.CrossRefPubMed
21.
go back to reference Kumkumian GK, Lafyatis R, Remmers EF, Case JP, Kim SJ, Wilder RL: Platelet-derived growth factor and IL-1 interactions in rheumatoid arthritis. Regulation of synoviocyte proliferation, prostaglandin production, and collagenase transcription. J Immunol. 1989, 143 (3): 833-837.PubMed Kumkumian GK, Lafyatis R, Remmers EF, Case JP, Kim SJ, Wilder RL: Platelet-derived growth factor and IL-1 interactions in rheumatoid arthritis. Regulation of synoviocyte proliferation, prostaglandin production, and collagenase transcription. J Immunol. 1989, 143 (3): 833-837.PubMed
22.
go back to reference Eastgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine FS, Duff GW: Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet. 1988, 2 (8613): 706-709. 10.1016/S0140-6736(88)90185-7.CrossRefPubMed Eastgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine FS, Duff GW: Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet. 1988, 2 (8613): 706-709. 10.1016/S0140-6736(88)90185-7.CrossRefPubMed
23.
go back to reference Tamura T, Matsubara M, Hasegawa K, Ohmori K, Karasawa A: Olopatadine hydrochloride suppresses the rebound phenomenon after discontinuation of treatment with a topical steroid in mice with chronic contact hypersensitivity. Clin Exp Allergy. 2005, 35 (1): 97-103. 10.1111/j.1365-2222.2005.02147.x.CrossRefPubMed Tamura T, Matsubara M, Hasegawa K, Ohmori K, Karasawa A: Olopatadine hydrochloride suppresses the rebound phenomenon after discontinuation of treatment with a topical steroid in mice with chronic contact hypersensitivity. Clin Exp Allergy. 2005, 35 (1): 97-103. 10.1111/j.1365-2222.2005.02147.x.CrossRefPubMed
24.
go back to reference Olmos A, Giner RM, Recio MC, Rios JL, Cerda-Nicolas JM, Manez S: Effects of plant alkylphenols on cytokine production, tyrosine nitration and inflammatory damage in the efferent phase of contact hypersensitivity. Br J Pharmacol. 2007 Olmos A, Giner RM, Recio MC, Rios JL, Cerda-Nicolas JM, Manez S: Effects of plant alkylphenols on cytokine production, tyrosine nitration and inflammatory damage in the efferent phase of contact hypersensitivity. Br J Pharmacol. 2007
25.
go back to reference Auron PE, Webb AC: Interleukin-1: a gene expression system regulated at multiple levels. Eur Cytokine Netw. 1994, 5 (6): 573-592.PubMed Auron PE, Webb AC: Interleukin-1: a gene expression system regulated at multiple levels. Eur Cytokine Netw. 1994, 5 (6): 573-592.PubMed
26.
go back to reference Shirakawa F, Saito K, Bonagura CA, Galson DL, Fenton MJ, Webb AC, Auron PE: The human prointerleukin 1 beta gene requires DNA sequences both proximal and distal to the transcription start site for tissue-specific induction. Mol Cell Biol. 1993, 13 (3): 1332-1344.PubMedCentralCrossRefPubMed Shirakawa F, Saito K, Bonagura CA, Galson DL, Fenton MJ, Webb AC, Auron PE: The human prointerleukin 1 beta gene requires DNA sequences both proximal and distal to the transcription start site for tissue-specific induction. Mol Cell Biol. 1993, 13 (3): 1332-1344.PubMedCentralCrossRefPubMed
27.
go back to reference Buras JA, Monks BG, Fenton MJ: The NF-beta A-binding element, not an overlapping NF-IL-6-binding element, is required for maximal IL-1 beta gene expression. J Immunol. 1994, 152 (9): 4444-4454.PubMed Buras JA, Monks BG, Fenton MJ: The NF-beta A-binding element, not an overlapping NF-IL-6-binding element, is required for maximal IL-1 beta gene expression. J Immunol. 1994, 152 (9): 4444-4454.PubMed
28.
go back to reference Buras JA, Reenstra WR, Fenton MJ: NF beta A, a factor required for maximal interleukin-1 beta gene expression is identical to the ets family member PU.1. Evidence for structural alteration following LPS activation. Mol Immunol. 1995, 32 (8): 541-554. 10.1016/0161-5890(95)00018-A.CrossRefPubMed Buras JA, Reenstra WR, Fenton MJ: NF beta A, a factor required for maximal interleukin-1 beta gene expression is identical to the ets family member PU.1. Evidence for structural alteration following LPS activation. Mol Immunol. 1995, 32 (8): 541-554. 10.1016/0161-5890(95)00018-A.CrossRefPubMed
29.
go back to reference Kominato Y, Galson D, Waterman WR, Webb AC, Auron PE: Monocyte expression of the human prointerleukin 1 beta gene (IL1B) is dependent on promoter sequences which bind the hematopoietic transcription factor Spi-1/PU.1. Mol Cell Biol. 1995, 15 (1): 58-68.PubMedCentralCrossRefPubMed Kominato Y, Galson D, Waterman WR, Webb AC, Auron PE: Monocyte expression of the human prointerleukin 1 beta gene (IL1B) is dependent on promoter sequences which bind the hematopoietic transcription factor Spi-1/PU.1. Mol Cell Biol. 1995, 15 (1): 58-68.PubMedCentralCrossRefPubMed
30.
go back to reference Galson DL, Hensold JO, Bishop TR, Schalling M, D'Andrea AD, Jones C, Auron PE, Housman DE: Mouse beta-globin DNA-binding protein B1 is identical to a proto-oncogene, the transcription factor Spi-1/PU.1, and is restricted in expression to hematopoietic cells and the testis. Mol Cell Biol. 1993, 13 (5): 2929-2941.PubMedCentralCrossRefPubMed Galson DL, Hensold JO, Bishop TR, Schalling M, D'Andrea AD, Jones C, Auron PE, Housman DE: Mouse beta-globin DNA-binding protein B1 is identical to a proto-oncogene, the transcription factor Spi-1/PU.1, and is restricted in expression to hematopoietic cells and the testis. Mol Cell Biol. 1993, 13 (5): 2929-2941.PubMedCentralCrossRefPubMed
31.
go back to reference Guglielmi L, Le Bert M, Truffinet V, Cogne M, Denizot Y: Insulators to improve expression of a 3(')IgH LCR-driven reporter gene in transgenic mouse models. Biochem Biophys Res Commun. 2003, 307 (3): 466-471. 10.1016/S0006-291X(03)01185-9.CrossRefPubMed Guglielmi L, Le Bert M, Truffinet V, Cogne M, Denizot Y: Insulators to improve expression of a 3(')IgH LCR-driven reporter gene in transgenic mouse models. Biochem Biophys Res Commun. 2003, 307 (3): 466-471. 10.1016/S0006-291X(03)01185-9.CrossRefPubMed
32.
go back to reference Zhang N, Weber A, Li B, Lyons R, Contag PR, Purchio AF, West DB: An inducible nitric oxide synthase-luciferase reporter system for in vivo testing of anti-inflammatory compounds in transgenic mice. J Immunol. 2003, 170 (12): 6307-6319.CrossRefPubMed Zhang N, Weber A, Li B, Lyons R, Contag PR, Purchio AF, West DB: An inducible nitric oxide synthase-luciferase reporter system for in vivo testing of anti-inflammatory compounds in transgenic mice. J Immunol. 2003, 170 (12): 6307-6319.CrossRefPubMed
33.
go back to reference Zhang N, Fang Z, Contag PR, Purchio AF, West DB: Tracking angiogenesis induced by skin wounding and contact hypersensitivity using a Vegfr2-luciferase transgenic mouse. Blood. 2004, 103 (2): 617-626. 10.1182/blood-2003-06-1820.CrossRefPubMed Zhang N, Fang Z, Contag PR, Purchio AF, West DB: Tracking angiogenesis induced by skin wounding and contact hypersensitivity using a Vegfr2-luciferase transgenic mouse. Blood. 2004, 103 (2): 617-626. 10.1182/blood-2003-06-1820.CrossRefPubMed
Metadata
Title
Functional imaging of interleukin 1 beta expression in inflammatory process using bioluminescence imaging in transgenic mice
Authors
Limei Li
Zhaoliang Fei
Jianke Ren
Ruilin Sun
Zhihui Liu
Zhejin Sheng
Long Wang
Xia Sun
Jun Yu
Zhugang Wang
Jian Fei
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Immunology / Issue 1/2008
Electronic ISSN: 1471-2172
DOI
https://doi.org/10.1186/1471-2172-9-49

Other articles of this Issue 1/2008

BMC Immunology 1/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.